SCHEMBL29325638

SCHEMBL29325638

COC(=O)c1ccc(-c2cnccn2)cc1C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.47
CYP46A1 Q9Y6A2 1/20 0.45
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
PIM2 Q9P1W9 2/20 0.43
PIM1 P11309 1/20 0.43
PORCN Q9H237 1/20 0.43
AXL P30530 2/20 0.43
NR4A2 P43354 1/20 0.43
WNT3A P56704 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ABL1 P00519 2/20 0.42
DHODH Q02127 1/20 0.42
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31056485 1.00 SLC2A1 (0.47) SLC2A1CYP46A1MKNK1MKNK2KDM4E
SCHEMBL29320335 0.86 CA12 (0.50) CYP46A1MKNK1MKNK2KDM4EALDH1A1
SCHEMBL27272854 0.85 ABL1 (0.44) KDM4EALDH1A1GLAGAAPIM2
SCHEMBL30987732 0.85 ABL1 (0.44) KDM4EALDH1A1GLAGAAPIM2
SCHEMBL29321962 0.85 MKNK1 (0.49) CYP46A1MKNK1MKNK2KDM4EALDH1A1
SCHEMBL7821127 0.84 SLC2A1 (0.68) SLC2A1CYP46A1KDM4EALDH1A1GAA
SCHEMBL27272872 0.82 ABL1 (0.44) CYP46A1KDM4EALDH1A1GLAGAA
SCHEMBL30987703 0.82 ABL1 (0.44) CYP46A1KDM4EALDH1A1GLAGAA
SCHEMBL30930680 0.82 AXL (0.58) KDM4EAXLHSD17B10ABL1DHODH
SCHEMBL27284549 0.82 AXL (0.58) KDM4EAXLHSD17B10ABL1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed